

Effects of Personalized Depression Prevention on Anxiety through 18-month Follow-up: A Randomized Controlled Trial

Date:

Sep 2022

[Visit Article](#)

Depression and anxiety frequently co-occur and share several risk factors. There is some evidence for transdiagnostic effects of prevention programs on depression and anxiety. In the Personalized Depression Prevention (PDP) study, youth ($n = 98$, $M_{age} = 13.94$ years, $SD = 1.67$) were classified as high or low on cognitive and interpersonal risk factors and randomized to either a cognitive-behavioral or an interpersonal prevention program. Some participants received a match between risk and prevention, others received a mismatch. Our initial work found evidence for the benefits of personalization on depression outcomes. In this paper, we focus on secondary anxiety outcomes through 18-months post-intervention. We found evidence for the benefits of personalized prevention on anxiety symptoms during the 18-month follow-up period, but not during the intervention. From post-intervention to 18-month follow-up matched youth showed a decrease in anxiety symptoms whereas mismatched youth showed a significant increase in symptoms ($d = 0.87$, $p = .001$). The rates of anxiety disorders were equivalent across the groups ($p = 1.00$). Given the comorbidity of depression and anxiety, interventions that have effects on both may be an efficient and cost-effective approach to reducing the burden associated with these conditions. A risk-informed personalization approach to prevention may be one way to enhance the transdiagnostic effects of depression prevention.

Journal:

[Behaviour Research and Therapy](#)

Authors:

Jones JD, Hankin BL, Gallop R, Haraden D, Sbrilli MD, Garber J, Young JF

Topics

[Evidence-based Prevention, Screening & Treatment](#)